TISIDB

Summary
Symbol	SULF2
Name	sulfatase 2
Aliases	KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum Golgi apparatus, Golgi stack Cell surface Note=Also localized on the cell surface.
Domain	PF12548 Sulfatase protein PF00884 Sulfatase
Function	Exhibits arylsulfatase activity and highly specific endoglucosamine-6-sulfatase activity. It can remove sulfate from the C-6 position of glucosamine within specific subregions of intact heparin.

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0001655 urogenital system development GO:0001819 positive regulation of cytokine production GO:0001822 kidney development GO:0001889 liver development GO:0002062 chondrocyte differentiation GO:0002063 chondrocyte development GO:0003012 muscle system process GO:0003014 renal system process GO:0003094 glomerular filtration GO:0006029 proteoglycan metabolic process GO:0006606 protein import into nucleus GO:0006790 sulfur compound metabolic process GO:0006913 nucleocytoplasmic transport GO:0006936 muscle contraction GO:0006939 smooth muscle contraction GO:0008543 fibroblast growth factor receptor signaling pathway GO:0009100 glycoprotein metabolic process GO:0010573 vascular endothelial growth factor production GO:0010574 regulation of vascular endothelial growth factor production GO:0010575 positive regulation of vascular endothelial growth factor production GO:0014831 gastro-intestinal system smooth muscle contraction GO:0014846 esophagus smooth muscle contraction GO:0016055 Wnt signaling pathway GO:0017038 protein import GO:0021675 nerve development GO:0022612 gland morphogenesis GO:0030111 regulation of Wnt signaling pathway GO:0030177 positive regulation of Wnt signaling pathway GO:0030198 extracellular matrix organization GO:0030201 heparan sulfate proteoglycan metabolic process GO:0031099 regeneration GO:0031100 animal organ regeneration GO:0032386 regulation of intracellular transport GO:0032388 positive regulation of intracellular transport GO:0032835 glomerulus development GO:0032836 glomerular basement membrane development GO:0033157 regulation of intracellular protein transport GO:0034504 protein localization to nucleus GO:0035411 catenin import into nucleus GO:0035412 regulation of catenin import into nucleus GO:0035413 positive regulation of catenin import into nucleus GO:0035860 glial cell-derived neurotrophic factor receptor signaling pathway GO:0040036 regulation of fibroblast growth factor receptor signaling pathway GO:0040037 negative regulation of fibroblast growth factor receptor signaling pathway GO:0042306 regulation of protein import into nucleus GO:0042307 positive regulation of protein import into nucleus GO:0043062 extracellular structure organization GO:0044344 cellular response to fibroblast growth factor stimulus GO:0044744 protein targeting to nucleus GO:0046822 regulation of nucleocytoplasmic transport GO:0046824 positive regulation of nucleocytoplasmic transport GO:0048706 embryonic skeletal system development GO:0048732 gland development GO:0050673 epithelial cell proliferation GO:0050678 regulation of epithelial cell proliferation GO:0051169 nuclear transport GO:0051170 nuclear import GO:0051216 cartilage development GO:0051222 positive regulation of protein transport GO:0060070 canonical Wnt signaling pathway GO:0060348 bone development GO:0060384 innervation GO:0060828 regulation of canonical Wnt signaling pathway GO:0061008 hepaticobiliary system development GO:0061448 connective tissue development GO:0071774 response to fibroblast growth factor GO:0072001 renal system development GO:0072006 nephron development GO:0072574 hepatocyte proliferation GO:0072575 epithelial cell proliferation involved in liver morphogenesis GO:0072576 liver morphogenesis GO:0090263 positive regulation of canonical Wnt signaling pathway GO:0090287 regulation of cellular response to growth factor stimulus GO:0090288 negative regulation of cellular response to growth factor stimulus GO:0090316 positive regulation of intracellular protein transport GO:0097205 renal filtration GO:0097421 liver regeneration GO:0198738 cell-cell signaling by wnt GO:1900180 regulation of protein localization to nucleus GO:1900182 positive regulation of protein localization to nucleus GO:1902593 single-organism nuclear import GO:1903533 regulation of protein targeting GO:1903829 positive regulation of cellular protein localization GO:1904589 regulation of protein import GO:1904591 positive regulation of protein import GO:1904951 positive regulation of establishment of protein localization GO:2000027 regulation of organ morphogenesis GO:2000345 regulation of hepatocyte proliferation
Molecular Function	GO:0004065 arylsulfatase activity GO:0008449 N-acetylglucosamine-6-sulfatase activity GO:0008484 sulfuric ester hydrolase activity
Cellular Component	GO:0005795 Golgi stack GO:0031984 organelle subcompartment GO:0098791 Golgi subcompartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	SULF2
Name	sulfatase 2
Aliases	KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SULF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SULF2
Name	sulfatase 2
Aliases	KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SULF2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SULF2
Name	sulfatase 2
Aliases	KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SULF2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.403	0.434
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.401	0.838
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.983	0.469
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.389	0.374
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.915	0.695
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.275	0.926
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.145	0.788
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.247	0.886
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.107	0.953
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.433	0.819
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.058	0.708
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.753	0.00173

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SULF2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	18.5	5.5	13	0.0572
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	18.5	6.8	11.7	0.132
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	0	22.2	0.12
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	0	40	0.11
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SULF2
Name	sulfatase 2
Aliases	KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SULF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SULF2
Name	sulfatase 2
Aliases	KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SULF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SULF2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SULF2
Name	sulfatase 2
Aliases	KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SULF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SULF2
Name	sulfatase 2
Aliases	KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SULF2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SULF2
Name	sulfatase 2
Aliases	KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SULF2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SULF2
Name	sulfatase 2
Aliases	KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SULF2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SULF2